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ABSTRACT
Objective Liver ﬁbrosis is associated with signiﬁcant
collagen-I deposition largely produced by activated
hepatic stellate cells (HSCs); yet, the link between
hepatocyte damage and the HSC proﬁbrogenic response
remains unclear. Here we show signiﬁcant induction of
osteopontin (OPN) and high-mobility group box-1
(HMGB1) in liver ﬁbrosis. Since OPN was identiﬁed as
upstream of HMGB1, we hypothesised that OPN could
participate in the pathogenesis of liver ﬁbrosis by
increasing HMGB1 to upregulate collagen-I expression.
Design and results Patients with long-term hepatitis
C virus (HCV) progressing in disease stage displayed
enhanced hepatic OPN and HMGB1 immunostaining,
which correlated with ﬁbrosis stage, whereas it remained
similar in non-progressors. Hepatocyte cytoplasmic OPN
and HMGB1 expression was signiﬁcant while loss of
nuclear HMGB1 occurred in patients with HCV-induced
ﬁbrosis compared with healthy explants. Well-established
liver ﬁbrosis along with marked induction of HMGB1
occurred in CCl4-injected Opn Hep transgenic yet it was
less in wild type and almost absent in Opn−/− mice.
Hmgb1 ablation in hepatocytes (Hmgb1 ΔHep) protected
mice from CCl4-induced liver ﬁbrosis. Coculture with
hepatocytes that secrete OPN plus HMGB1 and
challenge with recombinant OPN (rOPN) or HMGB1
(rHMGB1) enhanced collagen-I expression in HSCs,
which was blunted by neutralising antibodies (Abs) and
by Opn or Hmgb1 ablation. rOPN induced acetylation of
HMGB1 in HSCs due to increased NADPH oxidase
activity and the associated decrease in histone
deacetylases 1/2 leading to upregulation of collagen-I.
Last, rHMGB1 signalled via receptor for advanced
glycation end-products and activated the PI3K–pAkt1/2/
3 pathway to upregulate collagen-I.
Conclusions During liver ﬁbrosis, the increase in OPN
induces HMGB1, which acts as a downstream alarmin
driving collagen-I synthesis in HSCs.

INTRODUCTION

To cite: Arriazu E, Ge X,
Leung T-M, et al. Gut
2017;66:1123–1137.

Fibrogenesis encompasses qualitative and quantitative changes in the extracellular matrix (ECM)
deposits with a signiﬁcant buildup of collagen-I
ﬁbers, largely produced by activated hepatic stellate
cells (HSCs), which extensively distort the normal
hepatic architecture. Failure to degrade the

Signiﬁcance of this study
What is already known on this subject?

▸ Osteopontin (OPN) and high-mobility group
box-1 (HMGB1) are expressed in human and
mouse liver.
▸ We previously demonstrated the mechanisms
driving the increase in OPN in liver ﬁbrosis; yet,
whether OPN could increase HMGB1 has not
been established.
▸ If besides the proﬁbrogenic mechanisms
previously identiﬁed by us, OPN targets
HMGB1 to activate extracellular matrix
deposition by hepatic stellate cells (HSCs)
remained unknown.

What are the new ﬁndings?

▸ OPN and HMGB1 expression correlate with
ﬁbrosis stage in humans and mice.
▸ Using in vivo and in vitro loss or gain of
function approaches, we demonstrate that OPN
is upstream of HMGB1.
▸ Extracellular OPN promotes the acetylation
of intracellular HMGB1 in HSCs due to
increased NADPH oxidase activity and
the associated decrease in histone
deacetylases 1/2 leading to upregulation of
collagen-I.
▸ Extracellular HMGB1 signals HSCs via the
receptor for advanced glycation end-products
activating the PI3K–pAkt1/2/3 pathway to
increase collagen-I deposition.

How might it impact on clinical practice in
the foreseeable future?

▸ Identiﬁcation of key mediators along with
better understanding of the signalling pathways
they trigger to promote ﬁbrosis is critical to
prevent disease progression and design new
therapies. This study reinforces the role of
HMGB1, a hepatic sterile damage-associated
molecular pattern, in the progression of liver
ﬁbrosis. The role of OPN and HMGB1 on
collagen-I production by HSCs reveals novel
signalling mechanisms that could be targeted
for therapeutic beneﬁt.
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progressive increase in scar tissue is a major reason why ﬁbrosis
evolves into cirrhosis and hepatocellular carcinoma. To date,
extensive research has focused on identifying the key factors
involved in the pathogenesis of liver ﬁbrosis; yet, the precise
link between injured hepatocytes, HSCs and the ﬁbrogenic
response still remains poorly deﬁned.
We have previously shown that osteopontin (OPN), a matrixbound protein sensitive to oxidant stress and highly induced
upon liver damage, plays a central role in the pathogenesis of
liver ﬁbrosis by contributing to ECM deposition.1–3 Mechanistic
studies revealed ﬁrst that OPN upregulates collagen-I production
by HSCs via integrin αvβ3 engagement and activation of the
PI3K–pAkt1/2/3–NFκB signalling pathway;3 and second, that
OPN drives ductular reaction contributing to periportal scarring
by increasing transforming growth factor (TGF) β production in
biliary epithelial cells;1 yet, additional mediators downstream of
OPN, perhaps with proﬁbrogenic potential, could participate
increasing pathological collagen-I deposition by HSCs.
High-mobility group box-1 (HMGB1) is a nuclear nonhistone chromosomal protein that binds the DNA minor groove
and is involved in DNA replication, repair and energy homeostasis.4 Initially, it was believed that HMGB1 acted primarily as
an architectural protein. However, upon cellular injury and
post-translational modiﬁcations (PTMs), HMGB1 undergoes
translocation from the nucleus to the cytoplasm and is secreted
via the lysosomal pathway in most cells.5 HMGB1 signals via
the receptor for advanced glycation end-products (RAGE), tolllike receptors (TLRs)-2/4/9, Mac-1, syndecan-1, phosphacan
protein-tyrosine phosphatase-ζ/β and CD24.6
Recent work from our laboratory has demonstrated that
HMGB1 has noxious effects in the hepatic environment in the
setting of alcoholic liver disease.7 When released from injured
or necrotic cells due to loss of membrane integrity8 or when
secreted by hepatocytes in response to ethanol,7 HMGB1 can
trigger harmful responses. Thus, HMGB1 is now considered a
member of the family of damage-associated molecular patterns
(DAMPs) that communicate injury to neighbouring cells.
Although this alarmin increases in plasma and liver from alcoholic and ﬁbrotic patients,7 9 it is unknown whether it plays a
direct role in liver ﬁbrosis. Our preliminary in vivo observations
suggested that OPN is upstream of HMGB1 in hepatocytes and
HSCs. To date, whether OPN by increasing HMGB1 in a paracrine and/or in an autocrine fashion could regulate collagen-I
deposition in HSCs has not been demonstrated. Thus, we
hypothesised that OPN by upregulating HMGB1 could participate in the pathogenesis of liver ﬁbrosis driving scarring. Using
in vivo and in vitro loss-of-function or gain-of-function
approaches we focused on dissecting how the OPN and
HMGB1 axis in hepatocytes and HSCs regulates the HSC proﬁbrogenic behaviour. Overall, the data show that intracellular
OPN increases HMGB1 expression and extracellular OPN
induces acetylation of HMGB1 in HSCs due to increased
NADPH oxidase (NOX) activity and the associated decrease in
histone deacetylases (HDACs) 1/2 leading to upregulation of
collagen-I. Thus, OPN has autocrine and paracrine effects in
HSCs. Moreover, extracellular HMGB1 upregulates collagen-I
expression in HSCs paracrinely due to RAGE activation of the
PI3K–pAkt1/2/3 signalling pathway; thus, contributing to the
pathogenesis of liver ﬁbrosis.

MATERIALS AND METHODS
Mice

C57BL/6J wild-type (WT) and Opn−/− (B6.Cg-Spp1tm1Blh/J)
mice were obtained from the Jackson Laboratory (Bar Harbor,
1124

Maine, USA). Opn+/− mice were intercrossed and littermates
were used in all experiments. The Opn transgenic mice overexpressing OPN in hepatocytes (Opn Hep Tg) under the serum
amyloid-P component promoter were donated by Dr Mochida
(Saitama Medical University, Saitama, Japan).10 These mice
were crossbred for 10 generations with the same strain and
stock number of C57BL/6J WT listed above. The Hmgb1ﬂ/ﬂ
mice were donated by Dr Billiar (University of Pittsburgh,
Pittsburgh, Pennsylvania, USA). In these mice, the Hmgb1loxP
allele was created by inserting loxP sites within introns 1 and 2
ﬂanking exon 2 of Hmgb1.11 The Hmgb1ﬂ/ﬂ mice were bred
with Alb.Cre mice (the Jackson Laboratory) to generate
hepatocyte-speciﬁc Hmgb1ﬂ/ﬂAlb.Cre mice (abbreviated as
Hmgb1 ΔHep). All animals received humane care according to the
criteria outlined in the ‘Guide for the Care and Use of
Laboratory Animals’ prepared by the National Academy of
Sciences and published by the National Institutes of Health.

Statistical analysis
Data were analysed by a two-factor analysis of variance. All in
vitro experiments were performed in triplicate at least four
times. A representative blot is shown in all ﬁgures. Eight mice
per group were used in all the in vivo experiments, which were
repeated twice.

RESULTS
OPN and HMGB1 colocalise and their expression correlates
with ﬁbrosis progression in patients with chronic
HCV-induced ﬁbrosis
Since we hypothesised that OPN and HMGB1 could upregulate
collagen-I deposition in human liver ﬁbrosis, we determined
whether there was correlation between the induction of both
proteins and scarring. To this end, we analysed the expression
of OPN and HMGB1 in parafﬁn-embedded archived human
liver biopsies from deidentiﬁed controls and from patients with
clinically proven hepatitis C virus (HCV). The latter were paired
biopsy specimens, some of which showed progression of
HCV-induced ﬁbrosis ( progressors) and others did not (nonprogressors). Liver biopsies from patients with HCV showed
coinduction of both OPN and HMGB1 expression compared
with healthy explants (ﬁgure 1A, B). While their expression
remained akin over time in the non-progressors (ﬁgure 1A),
both proteins increased with ﬁbrosis stage in the progressors
(ﬁgure 1B). Computer-assisted morphometry assessment
demonstrated correlation between OPN and HMGB1 expression and ﬁbrosis stage in patients with chronic HCV infection
(ﬁgure 1C). Immunoﬂuorescence analysis proved co-localisation
of both proteins in patients with chronic HCV infection (ﬁgure
1D). Thus, these results suggest that OPN and HMGB1 colocalise and their expression correlates with ﬁbrosis progression in
patients with chronic HCV-induced ﬁbrosis.

OPN and HMGB1 colocalise and their expression correlates
in CCl4-induced liver injury in mice
To determine whether OPN is upstream of HMGB1 and dissect
if OPN induces HMGB1 therefore contributing to the ﬁbrogenic response to liver injury, we used the CCl4 model of liver
ﬁbrosis along with genetic manipulation of Opn using WT,
Opn−/−
and
Opn Hep
Tg
mice
as
previously.3
Immunohistochemistry
(IHC)
analysis
revealed
that
CCl4-injected Opn Hep Tg mice showed a marked increase in
hepatic OPN (ﬁgure 2A) and HMGB1 (ﬁgure 2B, top) expression compared with mineral oil (MO)-injected WT mice;
however, HMGB1 immunostaining was signiﬁcantly reduced in
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752
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Figure 1 Osteopontin (OPN) and
high-mobility group box-1 (HMGB1)
colocalise and their expression
correlates with ﬁbrosis progression in
patients with chronic HCV-induced
ﬁbrosis. H&E staining, OPN and
HMGB1 immunohistochemistry (IHC) in
parafﬁn-embedded archived human
liver biopsies from a deidentiﬁed
control and from a patient with
clinically proven hepatitis C virus
(HCV)-induced ﬁbrosis that did not
progress in disease stage (stage 2)
over 3 years show similar expression of
OPN (yellow arrows, insets) and
HMGB1 (green arrows, insets) (A).
H&E staining, OPN and HMGB1 IHC
from a patient with clinically proven
HCV-induced ﬁbrosis that progressed
from stage 2 to 3 in 3 years show
increased expression of OPN (yellow
arrows, insets) and HMGB1 (green
arrows, insets) (B). Total OPN and
HMGB1 morphometry analysis
according to ﬁbrosis stage. Results are
expressed as fold-change of the
healthy liver explants, which are
assigned a value of 1; n=10/group,
***p<0.001 for stages 1, 2, 3 or 4 vs
0 (C). Immunoﬂuorescence shows
colocalisation of OPN (red) and
HMGB1 (green) in a patient with
chronic HCV-induced ﬁbrosis at
stage 3 (D). DAPI, 40 ,6-diamidino2-phenylindole; IOD, integrated optical
density.

Opn−/− mice, which was also quantiﬁed by morphometry analysis and western blot (ﬁgure 2B, middle). Moreover, serum
HMGB1 doubled in CCl4-injected Opn Hep Tg compared with
WT mice (not shown). Since HMGB1 nucleocytoplasmic shuttling is critical for driving downstream events,7 HMGB1 localisation was quantiﬁed by computer-assisted morphometry
analysis. There was a signiﬁcant decrease in the ratio of
nuclear-to-total HMGB1 along with an increase in the ratio of
cytoplasmic-to-total HMGB1 expression in CCl4-injected
Opn Hep Tg compared with WT and it was lower in Opn−/− mice
(ﬁgure 2B, bottom). Immunoﬂuorescence analysis demonstrated
colocalisation of OPN and HMGB1 along with induced expression in CCl4-injected WT mice (ﬁgure 2C). OPN and HMGB1
expression signiﬁcantly increased in hepatocytes as shown by
colocalisation with HNF4α (nuclear staining)12 (ﬁgure 2D, top
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752

and middle). Similarly, HMGB1 expression was enhanced in
HSCs, although to a lesser extent than in hepatocytes, as shown
by colocalisation with desmin (ﬁgure 2D, bottom).
Furthermore, collagen-I deposition was greater in chronic
CCl4-injected Opn Hep Tg compared with WT but it was much
lesser in Opn−/− mice as shown by IHC and morphometry analysis (ﬁgure 2E). These in vivo results suggest the possibility that
OPN could drive HMGB1 release.

Hmgb1 ablation in hepatocytes partially prevents
CCl4-induced liver ﬁbrosis in mice
Since the human and mouse data suggested a possible role for
HMGB1 of hepatocyte origin in liver ﬁbrosis, to determine the
effect of blocking hepatocyte-derived HMGB1, Hmgb1 ΔHep
and control littermates were chronically injected MO or CCl4.
1125
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Figure 2 Osteopontin (OPN) and
high-mobility group box-1 (HMGB1)
colocalise and their expression
correlates in carbon tetrachloride
(CCl4)-induced liver injury in mice.
Wild-type (WT), Opn −/− and Opn Hep Tg
mice were injected with mineral oil
(MO) or CCl4 for 1 month. OPN (A)
and HMGB1 (B, top)
immunohistochemistry (IHC) and
morphometry analysis in livers from
CCl4-injected mice show increased
OPN (yellow arrows, insets) along with
HMGB1 (green arrows, insets)
expression, which is greater in
CCl4-injected Opn Hep Tg than in WT
and less in Opn −/− mice. Western blot
analysis for HMGB1 in livers from
MO-injected WT and CCl4-injected WT,
Opn−/− and Opn Hep Tg mice. The
results from the western blot analysis
are corrected by calnexin (loading
control) (B, middle). Quantiﬁcation of
nuclear, cytoplasmic, nuclear-to-total
and cytoplasmic-to-total HMGB1
expression (B, bottom).
Immunoﬂuorescence shows
colocalisation of OPN and HMGB1 as
well as induction in CCl4-injected WT
mice (C, top), which was quantiﬁed by
morphometry (C, bottom).
Immunoﬂuorescence demonstrates
colocalisation of OPN and HMGB1
with HNF4α (hepatocyte marker,
nuclear) along with induction by CCl4
treatment (D, top and middle). There is
also colocalisation of HMGB1 with
desmin (hepatic stellate cell (HSC)
marker, cytoplasmic) along with
induction by CCl4 treatment (D,
bottom). Collagen-I IHC and
morphometry assessment in livers from
MO-injected or CCl4-injected WT,
Opn−/− and Opn Hep Tg mice (E). In all
panels, the results are expressed as
fold-change of the WT mice injected
MO, which are assigned a value of 1
and are mean values±SEM; n=8/group.
*p<0.05, **p<0.01 and ***p<0.001
for CCl4-injected mice versus
MO-injected mice; ●p<0.05,
●●
p<0.01 and ●●●p<0.001 for
Opn Hep Tg or Opn −/− versus WT mice.
CV, central vein; DAPI,
40 ,6-diamidino-2-phenylindole; IOD,
integrated optical density; PV, portal
vein.
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Figure 2 Continued.

H&E staining, the pathology scores and serum alanine aminotransferase plus aspartate aminotransferase activities demonstrated less necrosis, inﬂammation, hepatocyte ballooning
degeneration and ﬁbrosis in CCl4-injected Hmgb1 ΔHep compared with control littermates (ﬁgure 3A). Similar results were
observed in a second model of liver ﬁbrosis induced by
common bile duct ligation (BDL) (see online supplementary
ﬁgure S1). Hmgb1 deletion in hepatocytes was conﬁrmed by
IHC in livers from Hmgb1 ΔHep and control littermates (ﬁgure
3B, top). IHC revealed less collagen-I expression in
CCl4-injected Hmgb1 ΔHep compared with control littermates
(ﬁgure 3B, top). Hmgb1 ablation did not affect OPN expression
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752

conﬁrming that OPN is upstream of HMGB1 (ﬁgure 3B, top).
The intensity of the positive staining from these proteins was
quantiﬁed by morphometry analysis (ﬁgure 3B, middle).
Similarly, Hmgb1 ablation did not alter RAGE expression
(ﬁgure 3B, bottom) or any other known HMGB1 receptor
mRNA (not shown). Thus, Hmgb1 ablation in hepatocytes partially prevents CCl4-induced liver ﬁbrosis in mice.

OPN is also upstream of HMGB1 in HSCs and they both
regulate collagen-I expression in an autocrine fashion in vitro
We previously demonstrated that HSCs express OPN1 and this
study revealed that HSCs also produce HMGB1. We next asked
1127
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Figure 3 Hmgb1 ablation in hepatocytes partially prevents carbon tetrachloride (CCl4)-induced liver ﬁbrosis in mice. Hmgb1 ΔHep and control
littermates were injected mineral oil (MO) or CCl4 for 1 month. H&E staining (A, top), the pathology scores (A, middle) and serum alanine
aminotransferase (ALT) plus aspartate aminotransferase (AST) activities (A, bottom) show lower necrosis, inﬂammation, hepatocyte ballooning
degeneration and ﬁbrosis in Hmgb1 ΔHep compared with control littermates. High-mobility group box-1 (HMGB1); green arrows, insets and collagen-I
immunohistochemistry (IHC) and morphometry analysis show reduced HMGB1 and collagen-I deposition in livers from CCl4-injected Hmgb1 ΔHep
compared with control littermates. IHC and western blot analysis demonstrate similar expression of osteopontin (OPN) and receptor for advanced
glycation end-products (RAGE) in these mice (B). The results are expressed as fold-change of the MO-injected control littermates, which are assigned
a value of 1 and are mean values±SEM; n=8/group. *p<0.05, **p<0.01 and ***p<0.001 for CCl4-injected versus MO-injected mice;
●
p<0.05, ●●p<0.01 and ●●●p<0.001 for Hmgb1 ΔHep versus control littermates. CV, central vein; IOD, integrated optical density; PV, portal vein;
WT, wild type.

whether HSC-derived OPN could exert an autocrine effect on
HMGB1 expression in HSCs and eventually on collagen-I
synthesis. Freshly isolated mouse WT and Opn−/− HSCs were
evaluated for OPN, HMGB1 and collagen-I expression. Opn−/−
showed a 90% reduction in intracellular HMGB1 as well as in
intracellular and extracellular collagen-I compared with WT
HSCs (ﬁgure 4A, left). Conversely, WT HSCs infected with an
adenovirus to overexpress OPN showed an increase in HMGB1
(ﬁgure 4A, right) and collagen-I3 expression compared with
HSCs infected with control LacZ adenovirus. To determine if
HMGB1 could condition OPN levels, WT and Hmgb1 −/−
mouse embryonic skin ﬁbroblasts (MEFs) were analysed for
OPN, HMGB1 and collagen-I expression. Hmgb1 −/− showed
similar intracellular OPN but a 90% reduction in intracellular
plus extracellular collagen-I expression compared with WT
MEFs (ﬁgure 4B). These data suggest that OPN is also upstream
of HMGB1 in HSCs and they both regulate collagen-I expression in vitro in an autocrine fashion.
1128

Hepatocytes are a major source of OPN and HMGB1
signalling to HSCs to increase collagen-I production
Since the human and mouse IHC suggested that hepatocytes are
a major source of both OPN and HMGB1, to further deﬁne
their paracrine involvement in the upregulation of collagen-I
production by HSCs, cocultures of primary hepatocytes from
MO-treated or CCl4-treated mice and HSCs were established.
First, the cocultures were incubated in the presence of neutralising antibodies (Abs) to OPN or HMGB1; and second, the
cocultures were established with hepatocytes from MO-treated
or CCl4-treated Opn−/−, Hmgb1 ΔHep and their respective
control littermates. Western blot analysis demonstrated an
increase in intracellular and extracellular collagen-I in HSCs
cocultured with WT hepatocytes from CCl4-treated mice (ﬁgure
4C, left and right, lane 3 in both blots); hence, HSCs were
responsive to hepatocyte-derived factors. These mediators were
identiﬁed as OPN and HMGB1, since incubation with neutralising Abs to each one of them prevented the collagen-I induction
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752
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Figure 3 Continued.

in HSCs (ﬁgure 4C, left and right, lane 4 in both blots).
Moreover, coculture with primary mouse hepatocytes from
CCl4-treated Opn−/− or Hmgb1 ΔHep mice downregulated intracellular and extracellular collagen-I in HSCs and blunted the
CCl4-mediated collagen-I increase (ﬁgure 4C left and right, lane
8 in both blots). Therefore, hepatocyte-derived OPN and
HMGB1 target HSCs and drive their proﬁbrogenic behaviour.

rOPN induces HMGB1 expression and translocation in HSC
and drives the increase in collagen-I production
Next, we examined if treatment with rOPN, as the upstream signal
and as a surrogate of the coculture model or paracrine effects,
could also replicate the increase in HMGB1 and collagen-I expression observed in HSCs. Primary rat HSCs cultured for 4 days (quiescent) or for 7 days (activated) and stimulated with rOPN
increased HMGB1 and collagen-I expression (ﬁgure 5A, left). The
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752

effects on HMGB1 were at the protein level since Hmgb1 mRNA
remained similar after the rOPN challenge (not shown) and inhibition of protein synthesis with cycloheximide blocked the increase
in HMGB1 by rOPN in HSCs (ﬁgure 5A, right).
Since HMGB1 undergoes nucleocytoplasmic shuttling in
response to a variety of stressors and PTMs,7 we next examined
whether rOPN could promote HMGB1 translocation from the
nucleus to the cytoplasm and eventually condition collagen-I
synthesis by HSCs. Western blot analysis of nuclear and cytoplasmic proteins from HSCs stimulated with rOPN proved that
the increase in cytoplasmic HMGB1 correlated with collagen-I
(ﬁgure 5B). These results were also validated by immunoﬂuorescence for HMGB1 and collagen-I in primary mouse HSCs
(ﬁgure 5C).
To further conﬁrm that following rOPN treatment, HMGB1
translocation drives collagen-I deposition, rat HSCs were
1129
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Figure 4 Osteopontin (OPN) is also upstream of high-mobility group box-1 (HMGB1) in hepatic stellate cells (HSCs) and they both regulate
collagen-I expression in an autocrine fashion in vitro. Primary HSCs from wild-type (WT) and Opn −/− mice were cultured for 5 days. Western blot
analysis of intracellular OPN, HMGB1 and collagen-I plus extracellular collagen-I expression (A, left). Rat HSCs were infected with Ad-LacZ or
Ad-OPN for 48 h. Western blot analysis of intracellular OPN and HMGB1 in rat HSCs infected with Ad-LacZ or Ad-OPN (A, right). Mouse embryonic
skin ﬁbroblasts (MEFs) from WT and Hmgb1 −/− mice were cultured for 1 day. Western blot analysis of intracellular OPN, HMGB1 and collagen-I plus
extracellular collagen-I expression (B). Hepatocytes are a major source of OPN and HMGB1 signalling to HSCs to increase collagen-I production.
Primary rat HSCs were cultured alone for 5 days and then cocultured with primary hepatocytes from mineral oil (MO)-treated or CCl4-treated Opn−/−,
Hmgb1 ΔHep and their matching control littermates for 1 day in the presence or absence of non-immune IgG or a neutralising antibody (Ab) to
HMGB1 or OPN, respectively. Western blot analysis of intracellular and extracellular collagen-I is shown (C). In all panels, the results are corrected by
the speciﬁc loading control and are expressed as fold-change of the control, which are assigned a value of 1 and are mean values±SEM; n=3/group.
Experiments were performed in triplicate four times. *p<0.05, **p<0.01 and ***p<0.001 for Ad-OPN or CCl4 versus Ad-LacZ or MO; ●p<0.05,
●●
p<0.01 and ●●●p<0.001 for Opn −/−, Hmgb1 −/−, HMGB1 Ab or OPN Ab versus WT or IgG; °p<0.05, °°p<0.01 and °°°p<0.001 for the Opn−/−
and Hmgb1 ΔHep coculture versus the WT and the control littermate cocultures.
transfected with constructs driving HMGB1 localisation to the
nucleus or to the cytoplasm and collagen-I expression was evaluated. The constructs were (1) pGFP, an empty vector used as a
negative control; (2) WT.Hmgb1.GFP, containing nuclear localisation signals (NLS) 1 and 2 to overexpress HMGB1 and allow
response to stimuli that could drive the protein to the cytoplasm
and (3) Hmgb1.NLS1/2(8K→8A).GFP, containing all eight
lysines in the two NLS mutated to alanines that cannot be acetylated therefore resulting in HMGB1 nuclear localisation13 (see
scheme on ﬁgure 5D).
In the absence of a stimulus, HSCs transfected with the WT.
Hmgb1.GFP or the Hmgb1.NLS1/2(8K→8A).GFP vectors
showed green ﬂuorescence only in the nucleus corresponding to
HMGB1 nuclear localisation (white arrows) compared with
HSCs transfected with the pGFP vector, which showed diffuse
green ﬂuorescence corresponding to GFP only. Treatment with
1130

rOPN increased collagen-I expression in WT.Hmgb1.
GFP-transfected HSCs only (red staining); still, rOPN induced
greater collagen-I expression (yellow arrows) in HSCs transfected with WT.Hmgb1.GFP showing cytoplasmic HMGB1
(white arrow heads) (ﬁgure 5E, top and middle panels, ﬁgure
5F). These results suggest that rOPN induces HMGB1 cytoplasmic localisation leading to an increase in collagen-I expression.
Moreover, transfection with the Hmgb1.NLS1/2(8K→8A).GFP
vector revealed that forced nuclear localisation of HMGB1
decreases the HSCs response to rOPN as less collagen-I was
observed compared with the WT.Hmgb1.GFP-transfected HSCs
(ﬁgure 5E, middle and bottom panels, ﬁgure 5F). Overall, these
experiments reveal that rOPN induces HMGB1 and collagen-I
expression in quiescent and activated HSCs and promotes
HMGB1 translocation from the nucleus to the cytoplasm thus
driving collagen-I production by HSCs; still, the mechanism for
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752
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Figure 5 Recombinant osteopontin (rOPN) induces high-mobility group box-1 (HMGB1) expression and translocation in hepatic stellate cells (HSCs)
and drives the increase in collagen-I production. Primary rat HSCs cultured for 4 days (quiescent) or 7 days (activated) were treated with rOPN for
6 h. Western blot analysis for intracellular HMGB1 and for intracellular plus extracellular collagen-I (A, left). Western blot analysis for HMGB1 in
primary rat HSCs treated with 50 nM rOPN for 6 h in the presence or absence of 100 mM cycloheximide (A, right). Primary rat HSCs cultured for
7 days were treated with rOPN for 6 h. Western blot analysis of nuclear plus cytoplasmic HMGB1 and intracellular collagen-I (B). In (A and B), the
results are expressed as fold-change of the corresponding control, which are assigned a value of 1 if signal is present and are mean values±SEM;
n=3/group in experiments performed in triplicate four times. *p<0.05, **p<0.01 and ***p<0.001 for rOPN versus control; ●●●p<0.001 for
cycloheximide cotreated versus rOPN. Primary mouse HSCs treated with 50 nM rOPN for 6 h. Immunoﬂuorescence analysis for HMGB1 (green) and
collagen-I (red) (C). HMGB1 structure and schematic representation of the lysine residues targeted in the HMGB1 constructs (D). Rat HSCs were
transfected with a series of constructs driving HMGB1 localisation followed by 0–50 nM rOPN treatment for 6 h. The constructs were (1) pGFP, an
empty vector as a negative control; (2) wild-type (WT).Hmgb1.GFP containing nuclear localisation signals 1 (NLS1) and NLS2 to overexpress HMGB1
and (3) Hmgb1.NLS1/2(8K→8A).GFP containing all eight lysines in the two NLS mutated to alanines, which cannot be acetylated and result in
nuclear localisation. Immunoﬂuorescence for collagen-I (yellow arrows) and GFP ﬂuorescence (HMGB1 localization: white arrows point at nuclear
HMGB1 and white arrowheads point at cytosolic HMGB1) were visualised by confocal microscopy (E) and quantiﬁed by morphometry assessment
(F). In (F), the results are expressed as fold-change of the control WT.Hmgb1.GFP, which are assigned a value of 1 and are mean values±SEM; n=3/
group in experiments performed in triplicate four times. *p<0.05, **p<0.01 and ***p<0.001 for rOPN versus control; ●●p<0.01 and ●●●p<0.001
for Hmgb1(8K→8A).GFP versus WT.Hmgb1.GFP. IOD, integrated optical density.
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Figure 6 Recombinant osteopontin
(rOPN) activates NADPH oxidase (NOX)
and inhibits histone deacetylases
(HDACs) 1/2 promoting high-mobility
group box-1 (HMGB1) acetylation and
translocation along with collagen-I
upregulation in hepatic stellate cells
(HSCs). Rat HSCs were treated with
rOPN for 6 h. Immunoprecipitation of
intracellular HMGB1 and
immunoblotting for acetylated lysines
(A). Identiﬁcation of the HMGB1
isoforms in HSCs lysates and in the cell
culture medium. Spectra of whole
protein electrospray ionisation–liquid
chromatography–mass spectrometry of
the HMGB1 isoforms. A schematic
representation of each isoform is on
each spectra (grey boxes); n=3/group
(B). Rat HSCs were treated with rOPN
for 2 h. Western blot analysis for PCAF
and p300 (C). Rat HSCs were treated
with rOPN for 1 and 2 h. Western blot
analysis for HDACs1-6 (D). NOX
activity in rat HSCs treated with rOPN
for 6 h alone or pretreated for 0.5 h
with apocynin or diphenyleneiodonium
(DPI), the two NOX inhibitors. The
percentage of dihydroethidium
(DHE)-positive cells was measured by
ﬂow cytometry as an indirect
measurement of O.−
2 production (E).
Rat HSCs were treated with rOPN for
6 h in the presence or absence of
apocynin or DPI. Western blot analysis
of HDACs1/2 along with intracellular
and extracellular collagen-I (F). The
results from the western blot analysis
are corrected by the speciﬁc loading
control and are expressed as
fold-change of the controls, which are
assigned a value of 1 and are mean
values±SEM; n=3/group in
experiments performed in triplicate
four times. *p<0.05, **p<0.01 and
***p<0.001 for rOPN versus control;
•p<0.05 and ••p<0.01 for cotreated
versus rOPN. HDACs, histone
deacetylases.

the mobilisation of HMGB1 in HSCs under rOPN treatment
remained undeﬁned.

rOPN activates NOX and inhibits HDACs1/2 promoting
HMGB1 acetylation and translocation along with collagen-I
upregulation in HSCs
As HMGB1 nucleocytoplasmic shuttling occurs in response to
stressors and/or PTMs,7 we examined if rOPN could trigger a
speciﬁc PTM in HSCs that would increase HMGB1.
Immunoprecipitation followed by immunoblotting revealed
signiﬁcant acetylation of HMGB1 in the presence of rOPN
(ﬁgure 6A). Using electrospray ionisation–liquid chromatography–mass spectrometry,7 we analysed the HMGB1 residues
modiﬁed under rOPN treatment in HSCs and found
Arriazu E, et al. Gut 2017;66:1123–1137. doi:10.1136/gutjnl-2015-310752

signiﬁcant acetylation in a cluster of eight lysines (28–30, 180
and 182–185), minimal oxidation of cysteines 23 and 45 and
no phosphorylation of serine 35 (ﬁgure 6B and not shown);
however, how these speciﬁc PTMs occurred remained
unknown.
Acetylation typically occurs due to enhanced histone acetyltransferases (HATs) and/or decreased HDACs activity; thus, we
measured the activity of HATs and HDACs. The activity of
HATs remained similar; however, there was a decrease in the
activity of HDACs in rOPN-treated HSCs compared with
control HSCs (not shown). Although PCAF ( p300/CBP-associated factor) and p300 have been described to acetylate
HMGB1;14 yet, western blot analysis revealed similar PCAF and
p300 expression in rOPN-stimulated HSCs compared with
1133
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control HSCs (ﬁgure 6C). Next, we analysed if the expression
of HDACs in HSCs changed under the rOPN challenge.
Western blot analysis demonstrated a decrease in HDACs1/2,
whereas HDACs3–6 remained similar in rOPN-stimulated HSCs
compared with control HSCs (ﬁgure 6D). Thus, rOPN acetylates HMGB1 likely by inhibiting HDACs1/2, which could contribute to HMGB1 cytoplasmic accumulation. Nevertheless,
how inhibition of HDACs1/2 occurred remained undeﬁned.
HDACs activity can be inhibited by activation of NOX with
the subsequent generation of reactive oxygen species.15 To
establish if rOPN could activate NOX and inhibit HDACs1/2 in
HSCs, we measured NOX activity and O.−
2 production and
found an increase in NOX activity and O.−
2 levels. When NOX
induction was blocked by apocynin or diphenyleneiodonium
(DPI) chloride, the two NOX inhibitors (ﬁgure 6E), they prevented the rOPN-mediated decrease in HDACs1/2 and the
increase in collagen-I expression in HSCs (ﬁgure 6F). Overall,
these results provide proof of concept that rOPN activates NOX
to induce the production of O.−
2 , which inhibits HDACs1/2
expression, allows HMGB1 acetylation and upregulates
collagen-I synthesis by HSCs.

rHMGB1 signals via the PI3K–pAkt1/2/3 pathway to
upregulate collagen-I expression in HSCs
Since the human and mouse data along with the coculture
studies suggested that hepatocytes produce and secrete
HMGB1, which was identiﬁed as downstream of OPN, we next
asked if extracellular HMGB1 per se could also signal to HSCs
and increase collagen-I synthesis. To address this question, HSCs
were challenged with rHMGB1, which did not alter OPN
expression, yet increased intracellular and extracellular
collagen-I (ﬁgure 7A). Since collagen-I production is highly
dependent from protein kinase activation, to better understand
how rHMGB1 upregulated collagen-I synthesis in HSCs, we
analysed the expression of a series of protein kinases to determine their potential activation by rHMGB1. Following
1134

evaluation of the expression and phosphorylation state of
protein kinases known to activate collagen-I synthesis (ie, ERK1/
2, PI3K, Akt, p70RSK, p38, JNK), we identiﬁed that rHMGB1
time-dependently increased PI3K and induced the phosphorylation of Akt1/2/3, its downstream target (ﬁgure 7B). To conﬁrm
that they were indeed involved in the effects of rHMGB1 on
collagen-I production by HSCs, cells were preincubated with
the PI3K inhibitors wortmannin or LY294002 and then challenged with rHMGB1. Western blot analysis revealed a decrease
in collagen-I production under rHMGB1 treatment when cells
were pretreated with inhibitor, thus validating the role of PI3K
and pAkt1/2/3 in the effects of rHMGB1 on collagen-I expression in HSCs (ﬁgure 7C). Therefore, extracellular HMGB1 per
se also upregulates collagen-I in HSCs via PI3K–pAkt1/2/3
signalling.

rHMGB1 signals via RAGE to upregulate collagen-I
expression through the PI3K–pAkt1/2/3 pathway in HSCs
Last, since HMGB1 binds several receptors, of which RAGE16
and TLRs2/4/917–19 have been described to play a role in the
setting of liver ﬁbrosis, we evaluated whether the HMGB1
effects on collagen-I were receptor-mediated. To this end, we
ablated Rage or Tlrs2/4/9 using shRNA lentiviral particles or
siRNA strategies. Upon successful ablation (ﬁgure 7D and not
shown), HSCs were treated with rHMGB1 and collagen-I
expression was evaluated. RAGE (ﬁgure 7D) but not TLRs2/4/9
(see online supplementary ﬁgure S2) was critical for the effects
of rHMGB1 on collagen-I upregulation in HSCs since western
blot analysis showed upregulation of collagen-I following
rHMGB1 treatment, without altering RAGE expression but not
after Rage ablation (ﬁgure 7D). To identify whether the PI3K–
pAkt1/2/3
signalling
pathway
was
activated
in
a
RAGE-dependent manner, we analysed the expression of these
proteins and found no activation of PI3K and pAkt1/2/3 after
rHMGB1 treatment when Rage was ablated (ﬁgure 7D).
Overall, these results suggest that rHMGB1 signals via RAGE
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Figure 7 rHMGB1 signals via
receptor for advanced glycation
end-products (RAGE) to upregulate
collagen-I expression through the
PI3K–pAkt1/2/3 pathway in hepatic
stellate cells (HSCs). Rat HSCs were
treated with 50 nM rHMGB1 for 6 h.
Western blot analysis for intracellular
plus extracellular OPN and collagen-I
(A). HSCs were challenged with
rHMGB1 up to 6 h and western blot
analysis was performed for PI3K,
pAkt1/2/3 and Akt1/2/3 (B). Western
blot for pAkt1/2/3, pAkt1/2/3 and
intracellular plus extracellular
collagen-I in HSCs treated with
rHMGB1 in the presence or absence of
wortmannin or LY294002 (two PI3K
inhibitors) (C). Rage ablation was
performed in HSCs by transduction
with shRNA lentiviral particles and
isolation of stable clones expressing
the shRNA via puromycin
dihydrochloride selection. Cells were
treated with rHMGB1 for 6 h followed
by western blot analysis for RAGE,
PI3K, pAkt1/2/3, Akt1/2/3 intracellular
and extracellular collagen-I (D). The
results from the western blot analysis
are corrected by the speciﬁc loading
control and are expressed as
fold-change of the controls, which are
assigned a value of 1 and are given as
mean values±SEM; n=3/group in
experiments performed in triplicate
four times. *p<0.05, **p<0.01 and
***p<0.001 for rHMGB1 versus
control; •p<0.05, ••p<0.01 and
•••p<0.001 for cotreated or Rage
ablated versus rHMGB1 or Gfp.
Wild-type (WT) mice were injected CCl4
for 1 month along with non-immune
IgG or RAGE neutralising Ab. H&E
staining and collagen-I
immunohistochemistry (IHC) and
morphometry analysis showing that
neutralisation of RAGE protects mice
from liver ﬁbrosis (E). The results are
expressed as fold-change of the IgG
group, which are assigned a value of 1
and are given as mean values±SEM;
n=3/group. ••p<0.01 for RAGE Ab
versus IgG. CV, central vein; PV, portal
vein.
and activates the PI3K–pAkt1/2/3 pathway to upregulate
collagen-I in HSCs. Last, to conﬁrm the role of RAGE in the
collagen-I upregulation in liver ﬁbrosis in vivo, WT mice were
chronically injected CCl4 in the presence of non-immune IgG
or a RAGE neutralising Ab. Blockade of RAGE partially prevented liver ﬁbrosis compared with mice injected with an irrelevant isotype-matched control monoclonal antibody (ﬁgure 7E).

DISCUSSION
Since the incidence of liver ﬁbrosis is rising worldwide, there is
a pressing need to identify novel targets and design new therapies to prevent disease onset and/or progression. To date, most of
the research in this ﬁeld has focused on identifying the events
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involved in the pathogenesis of liver ﬁbrosis; yet, the precise
link between injured hepatocytes, HSCs and scarring remained
to be identiﬁed. Thus, our goal was to dissect if OPN targets
HMGB1 and how the upregulation of both proteins in hepatocytes and in HSCs contributes to the pathogenesis of liver ﬁbrosis by regulating scarring.
This study provides compelling evidence for both
co-localisation and correlation of the expression of OPN and
HMGB1 with ﬁbrosis progression in patients with clinically
proven HCV-induced ﬁbrosis.
To determine if OPN is upstream of HMGB1 and to dissect if
it targets it contributing, via yet to be established mechanisms,
to the ﬁbrogenic response to liver injury, we used the CCl4
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model of liver ﬁbrosis along with genetic manipulation of Opn
in mice. In addition to an increase in co-localisation of OPN
and HMGB1, rather remarkable in hepatocytes, their expression
correlated with the extent of liver ﬁbrosis in mice. Importantly,
ﬁbrosis was signiﬁcantly greater in chronic CCl4-injected
Opn Hep Tg compared with WT and it was much lesser in Opn −/
−
mice.3 Moreover, we observed that ageing Opn Hep Tg mice
showed enhanced expression of hepatic OPN and HMGB1 and
developed spontaneous ﬁbrosis3 in the absence of a proﬁbrogenic stimulus (see online supplementary ﬁgure S3). Overall,
these in vivo results suggested that OPN is upstream of HMGB1
and that the increase in OPN, likely driving HMGB1, plays a
major role in the pathogenesis of liver ﬁbrosis in mice; yet, the
speciﬁc mechanism whereby HMGB1 could act as a proﬁbrogenic paracrine and/or autocrine DAMP remained unknown.
We have previously established two mechanisms whereby
OPN contributes to liver ﬁbrosis in vivo. Since the colocalisation
studies in human and mice also suggested a possible role for
hepatocyte-derived HMGB1 in liver ﬁbrosis, next we evaluated
the consequences of blocking HMGB1 in hepatocytes for the
development of liver ﬁbrosis. We demonstrated that selective
ablation of Hmgb1 in hepatocytes partially prevented
CCl4-induced liver ﬁbrosis in mice, which was also validated in
the BDL model.
To further deﬁne the paracrine involvement of hepatocytederived OPN and HMGB1 in the upregulation of collagen-I
production by HSCs, cocultures of hepatocytes with HSCs were
established. These experiments demonstrated that hepatocytes
are a major source of OPN and HMGB1 in addition to a paracrine role in increasing collagen-I production by HSCs. This
was further proven by the blocking effect of neutralising Abs to
OPN or HMGB1 and by hepatocyte-speciﬁc ablation of Opn or
Hmgb1 in the cocultures. In both cases, collagen-I synthesis in
HSCs was signiﬁcantly reduced however far more when Hmgb1
was ablated. Hence, hepatocyte-derived OPN and HMGB1
target HSCs and drive their proﬁbrogenic behaviour.
Once the role of hepatocyte-derived OPN and HMGB1 was
established, we then asked if intracellular OPN and HMGB1 in
HSCs could also play an autocrine role driving scarring. Since we
previously demonstrated that HSCs express OPN1 and the
present study revealed induction of HMGB1 under OPN treatment, we next ablated both proteins. Analysis of the autocrine
effects resulting from (1) regulating Opn expression for HMGB1
production and (2) modulating Hmgb1 expression for collagen-I
synthesis suggested that intracellular OPN is also upstream of
HMGB1 in HSCs and regulates collagen-I expression.
Next, to dissect the molecular mechanism for the paracrine
effects of OPN and HMGB1 for the HSCs proﬁbrogenic behaviour, we treated HSCs with rOPN or rHMGB1. We previously
showed that rOPN upregulates collagen-I production in HSCs
by binding αvβ3 integrin and activating the PI3K–pAkt1/2/3–
NFκB signalling pathway in addition to driving ductular reaction and increasing TGF-β production in biliary epithelial
cells.1 3 Yet, in view of our data, we also considered that a
downstream target of OPN, such as HMGB1, could participate
in increasing collagen-I deposition thereby contributing to the
pathophysiology of liver ﬁbrosis by regulating scarring.
Extracellular OPN induced HMGB1 and collagen-I expression in quiescent and activated HSCs and also promoted
HMGB1 translocation from the nucleus to the cytoplasm
driving collagen-I production by HSCs as demonstrated with
the transfection experiment using the constructs conditioning
HMGB1 subcellular localisation in response to stimuli. The construct preventing HMGB1 acetylation in HSCs under rOPN
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treatment suggested a key role of a PTM for collagen-I production in this setting. Indeed, analysis of the potential PTMs
revealed extensive acetylation of HMGB1 in the cluster of eight
lysines (28–30, 180 and 182–185) under OPN treatment in
HSCs, which could explain the cytoplasmic increase in HMGB1
since acetylation prevents HMGB1 nuclear re-entry. To understand how this modiﬁcation occurred, next we measured HATs
and HDACs activity along with the expression of each of these
proteins. OPN lowered HDACs1/2 activity and acetylated
HMGB1 thus contributing to HMGB1 cytoplasmic localisation
and increase. Furthermore, OPN activated NOX and stimulated
O.−
2 generation, which ultimately inhibited HDACs1/2 expression allowing HMGB1 acetylation and upregulating collagen-I
expression in HSCs. Thus, extracellular OPN can paracrinely
promote the autocrine effects of HSC-derived HMGB1 in
driving collagen-I deposition.
Finally, the human and mouse data along with the coculture
studies suggested that hepatocytes were a major source of
HMGB1, which was identiﬁed as downstream of OPN.
Of note, while hepatocytes secrete a considerable amount of
HMGB1,7 HSCs secrete it but to a much lesser degree. Next,
we demonstrated that extracellular HMGB1 per se also signals
to HSCs via RAGE signalling and activation of the PI3K–pAkt1/
2/3 pathway to upregulate collagen-I in HSCs. Therefore, RAGE
plays a major role in the HMGB1-mediated effects on collagen-I
synthesis in the setting of liver ﬁbrosis.
While the involvement of HMGB1 in other liver diseases has
been reported,20–25 the role of HMGB1 in liver ﬁbrosis has not
been fully evaluated to date. Hence, we have identiﬁed that
during the onset of liver ﬁbrosis, the increase in OPN, and as a
consequence in HMGB1, drives scarring. As proposed in this
study (see online supplementary ﬁgure S4), the signiﬁcant upregulation of this alarmin has critical paracrine and autocrine
effects on HSCs and therefore it could be targeted to prevent or
slow down the ﬁbrogenic process.
Overall, this study challenged our current view of the mechanisms driving liver disease by reinforcing the role of hepatic OPN
and HMGB1, a sterile DAMP, in the onset of liver ﬁbrosis and
tested the novel hypothesis that during ﬁbrogenesis the increase
in OPN, and as a consequence in HMGB1, acts as a paracrine
and autocrine signal to trigger scarring. Development of efﬁcient
therapies for liver ﬁbrosis must target the molecular mechanisms
driving early ﬁbrosis related to hepatocellular injury to allow
rapid intervention. Importantly, HMGB1 has the advantage that,
unlike other proteins, provides a wider time frame for clinical
intervention due to its longer half-life.26 Thus, it is an attractive
target to prevent ﬁbrosis progression. OPN and HMGB1 may
also participate in other events taking place in liver ﬁbrosis such
as necrosis, inﬂammation and increased gut permeability. Finally,
due to the extent of their production in hepatocytes, it is likely
that the overall contribution of hepatocyte-derived OPN and
HMGB1 to scarring is far more relevant than that of HSCs. It
still remains an open question if their production in other liver
cells or in other organs is also relevant or perhaps synergistic for
liver ﬁbrosis and if speciﬁc PTMs of HMGB1 could also condition the noxious effects of HMGB1 in the liver environment.
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